Chelsea Taylor

Nov 19, 2024 | cell.com | Jana Obajdin |Daniel Larcombe-Young |Maya Glover |Caroline Hull |Katie Flaherty |Ge Tan | +13 more

Keywordschimeric antigen receptorNKG2DDap10Dap12adaptorIntroductionNKG2D is expressed by natural killer (NK) cells, CD8+ αβ T cells, γδ T cells, invariant NKT cells, and some CD4+ T cell subsets.1 It mediates the recognition of cells that express any of the eight NKG2D ligands (NKG2DLs), namely MHC class I polypeptide-related sequence (MIC)A/B and UL16-binding protein (ULBP)1–6.

Nov 6, 2024 | biorxiv.org | Esther Ng |Orion Tong |Chelsea Taylor |Robert Watson

AbstractCD8+ T cells play a central role in the cancer response to immune checkpoint blockade (ICB) treatment, with activity predicated upon antigen recognition by the associated T cell receptor (TCR) repertoire. The contribution of genetic variation to this in cancer treatment is under-explored.